April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Integrating Olaparib into Clinical Practice Represents Important Step for Oncologists, Patients
February 17th 2015To gain insight into the integration of olaparib (Lynparza) into clinical practice, Targeted Oncology interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.
Read More
Expert Investigators Discuss Emerging Therapies for GI Cancers
February 11th 2015A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.
Read More
Early Research Under Way to Improve Drug Delivery in Ovarian Cancer
February 10th 2015Targeted agents have become available in recent years to treat many major cancers, but for women with ovarian cancer, standard treatment following cytoreductive surgery remains systemic intravenous/intraperitoneal chemotherapy with a platinum agent and a taxane. Approximately 80% of women who receive first-line treatment with this platinum-based regimen experience relapsed disease. However, early research indicates that more and better options may be on the way.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
MET Inhibitor AMG-337 Shows Promise in Some Patients with Advanced Gastroesophageal Cancer
January 17th 2015Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.
Read More
New York State Awards Grant for First Stem-Cell Immunotherapy Trial in Ovarian Cancer
January 16th 2015The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.
Read More
Ovarian Suppression Lowers Risk of Recurrence in Younger, Premenopausal Breast Cancer Patients
December 12th 2014Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or—to a lesser extent—tamoxifen, compared with standard tamoxifen alone.
Read More
Nilotinib Efficacious in Elderly Patients With Philadelphia-Positive ALL
December 8th 2014Treatment with nilotinib (Tasigna) in combination with chemotherapy elicited complete hematological remissions (CHR) in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
CAR T-Cell Therapy CTL019 Demonstrates 92% Response Rate in Pediatric ALL
December 7th 2014The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
Cirmtuzumab Blocks Ovarian Cancer Metastasis in Preclinical Study
November 18th 2014The monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.
Read More
Molecular Discoveries Yield Many Personalized Treatment Targets in Ovarian Cancer
November 7th 2014Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
Read More
The State of PARP Inhibitors in Ovarian Cancer: Many Agents, Many Questions
November 7th 2014PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.
Read More
Trebananib Does Not Improve Survival in Ovarian Cancer
November 5th 2014A statistically significant improvement in overall survival (OS) was not seen with the combination of paclitaxel and the angiogenesis inhibitor trebananib when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.
Read More